Expert Interview
Evaluating the Future Treatment Landscape for Lipoprotein(a) management and the Potential of Pelacarsen (Novartis), Olpasiran (Amgen), and Lepodisiran (Eli Lilly)
Ticker(s): AMGN, NVS, LLYInstitution: Western University
- Distinguished Professor of Medicine and Biochemistry at Western University in London, Ontario, Canada.
- Manages >2500 patients in his lipid clinic, 25 with FCS.
- His laboratory discovered the causal genes and first pathogenic variants for >20 human diseases, and also developed the world’s first targeted next-generation sequencing panel for dyslipidemias.
- He was among the first in the world to use five medications that are now routinely prescribed to treat dyslipidemia or diabetes, has co-authored many clinical practice guidelines for cholesterol, blood pressure and diabete, and has published >900 papers.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 14, 2026
- Call Time
- 03:00 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
